Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Janssen: Sales Up 2.7% to ¥80.5 Bil.
May 17, 2010
- Takeda Applies for Successor of Blopress in the US
May 17, 2010
- Good Control of Nocturnal Respiratory Symptoms Important in Children: Prof. Mochizuki
May 17, 2010
- Torii to Boost Sales to ¥50 Bil. by FY2012
May 17, 2010
- Eisai Applies for Reflux Esophagitis for Pariet
May 17, 2010
- Treatment Cost Holds Key in Selection of ARB/CCB Combinations: Dr Ogihara
May 17, 2010
- METI Presents Report on Pharma Industry Promotion
May 17, 2010
- Abbott Japan Applies for Kaletra for Once Daily Treatment
May 17, 2010
- Chugai to Educate Top Oncology MRs
May 17, 2010
- How Will Distribution Practice Be Improved Following Pricing System Reform? (1)
May 17, 2010
- DSP's Eslicarbazepine Not Approved by FDA
May 17, 2010
- How Will Distribution Practice Be Improved Following Pricing System Reform? (2)
May 17, 2010
- 2 Chemo Regimens Approved as Advanced Healthcare Services
May 17, 2010
- Santen Licenses ATL313 from Clinical Data
May 17, 2010
- Peptide Vaccine Therapy for Bladder Cancer Recommended for Conditional Approval
May 17, 2010
- Kissei Licenses Proaerolysin from Protox
May 17, 2010
- Package Inserts for DPP-4 Inhibitors, GLP-1 Analogue to Be Modified
May 17, 2010
- Takeda Settles Actos Patent Infringement Litigations in US
May 17, 2010
- Reimbursement Method to Be Reviewed for 23 Products
May 17, 2010
- Korosho's Growth Strategy Calls For Development of New Drugs, Medical Devices
May 17, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…